Evidence map›Paper›PMID 27199655›Full record

ReviewFrontiers in molecular neuroscience2016

CRISPR/Cas9: Implications for Modeling and Therapy of Neurodegenerative Diseases.

Weili Yang, Zhuchi Tu, Qiang Sun, Xiao-Jiang Li

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in molecular neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Ageing, Neurodegeneration and the Endocannabinoid System.Current topics in behavioral neurosciences · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Bioethical issues in genome editing by CRISPR-Cas9 technology.Turkish journal of biology = Turk biyoloji dergisi · 2020
    Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Weili YangInstitute of Genetics and Developmental Biology, Chinese Academy of Sciences Beijing, China.
Zhuchi TuInstitute of Genetics and Developmental Biology, Chinese Academy of Sciences Beijing, China.
Qiang SunInstitute of Genetics and Developmental Biology, Chinese Academy of Sciences Beijing, China.
Xiao-Jiang LiInstitute of Genetics and Developmental Biology, Chinese Academy of SciencesBeijing, China; Department of Human Genetics, Emory University School of MedicineAtlanta, GA, USA.
Chinese Academy of Sciences · CN

Funding

Nuclear Toxicity of Huntington Disease ProteinR01NS041669 · NINDS · EMORY UNIVERSITY · PI LI, XIAO-JIANG · 2001 to 2015
$4.6M
Synaptic toxicity of Huntington disease proteinR01AG019206 · NIA · EMORY UNIVERSITY · PI LI, XIAO-JIANG · 2001 to 2016
$4.5M
NIA NIH HHS R01 AG019206NINDS NIH HHS R01 NS041669
6 · The paper itself

Abstract

CRISPR/Cas9 is now used widely to genetically modify the genomes of various species. The ability of CRISPR/Cas9 to delete DNA sequences and correct DNA mutations opens up a new avenue to treat genetic diseases that are caused by DNA mutations. In this review, we describe the advantages of using CRISPR/Cas9 to engineer genomic DNAs in animal embryos, as well as in specific regions or cell types in the brain. We also discuss how to apply CRISPR/Cas9 to establish animal models of neurodegenerative diseases, such as Parkinson's and Huntington's disease (HD), and to treat these disorders that are caused by genetic mutations.

Indexed as

animal modelsCRISPR/Cas9neurodegenerative diseases

Identifiers

PMID27199655
PMCPMC4848312
OpenAlexW2343427612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.